Nothing Special   »   [go: up one dir, main page]

MX2022002366A - Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente. - Google Patents

Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.

Info

Publication number
MX2022002366A
MX2022002366A MX2022002366A MX2022002366A MX2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A
Authority
MX
Mexico
Prior art keywords
fully
diabetic retinopathy
translationally modified
treatment
modified anti
Prior art date
Application number
MX2022002366A
Other languages
English (en)
Inventor
Everen Sherri Van
Jesse I Yoo
Samir Maganbhai Patel
Avanti Arvind Ghanekar
Kim Rees Irwin-Pack
Darin Thomas Curtiss
Stephen Joseph Pakola
Anthony Ray O''berry
Original Assignee
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc filed Critical Regenxbio Inc
Publication of MX2022002366A publication Critical patent/MX2022002366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen composiciones y métodos para la administración de un anticuerpo monoclonal ("mAb") completamente humano modificado postraduccionalmente (HuPTM) o el fragmento de unión al antígeno de un mAb contra el factor de crecimiento endotelial vascular humano ("hVEGF"), como, por ejemplo, un fragmento de unión al antígeno anti-hVEGF completamente glicosilado humano (HuGly), a la retina/humor vítreo en el ojo o los ojos de sujetos humanos diagnosticados con retinopatía diabética.
MX2022002366A 2019-08-26 2020-08-25 Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente. MX2022002366A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962891799P 2019-08-26 2019-08-26
US201962902352P 2019-09-18 2019-09-18
US202063004258P 2020-04-02 2020-04-02
PCT/US2020/047733 WO2021041373A1 (en) 2019-08-26 2020-08-25 Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab

Publications (1)

Publication Number Publication Date
MX2022002366A true MX2022002366A (es) 2022-07-19

Family

ID=72473961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002366A MX2022002366A (es) 2019-08-26 2020-08-25 Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.

Country Status (12)

Country Link
US (1) US20220280608A1 (es)
EP (1) EP4021936A1 (es)
JP (1) JP2022545967A (es)
KR (1) KR20220051246A (es)
CN (1) CN114502197A (es)
AU (1) AU2020336314A1 (es)
BR (1) BR112022003811A2 (es)
CA (1) CA3149401A1 (es)
IL (1) IL290863A (es)
MX (1) MX2022002366A (es)
TW (1) TW202122419A (es)
WO (1) WO2021041373A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126329A1 (en) 2017-12-19 2019-06-27 Akouos Llc Aav-mediated delivery of therapeutic antibodies to the inner ear
WO2024073669A1 (en) 2022-09-30 2024-04-04 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
WO2024178225A1 (en) * 2023-02-22 2024-08-29 Cornell University Gene therapy mediated angiogenesis to enhance survival of transplanted fat

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE453709T1 (de) 1993-02-12 2010-01-15 Univ Leland Stanford Junior Regulierte transkription von zielgerichteten genen und andere biologische ereignisse
JP3817739B2 (ja) 1994-12-29 2006-09-06 マサチューセッツ・インスティテュート・オブ・テクノロジー キメラｄｎａ結合性タンパク質
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白
EP1003886A1 (en) 1997-08-27 2000-05-31 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
JP2002503667A (ja) 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
ES2478635T3 (es) 1999-08-09 2014-07-22 Targeted Genetics Corporation Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
DE60209193T2 (de) 2001-11-13 2006-09-28 Trustees Of The University Of Pennsylvania Verfahren zur Identifizierung von Adeno-assoziiertem Virus (AAV) Sequenzen sowie Kit zur Ausführung der Methode
PT2359869T (pt) 2001-12-17 2019-04-16 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
CN102199626B (zh) 2003-09-30 2015-06-24 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
CN103189507A (zh) 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
EP4234571A3 (en) 2011-02-10 2023-09-27 The University of North Carolina at Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
LT3254703T (lt) 2011-04-22 2020-05-25 The Regents Of The University Of California Adenoasocijuoto viruso virionai su variantine kapside ir jų panaudojimo būdai
EP3147295B2 (en) 2011-08-24 2023-11-22 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
EP2847337A4 (en) 2012-05-09 2016-04-27 Univ Oregon Health & Science PLASMIDS AND VIRAL VECTORS ASSOCIATED WITH ADENOVIRUS
WO2013177215A1 (en) 2012-05-24 2013-11-28 Altaviz Llc Viscous fluid injector
AU2014244167A1 (en) 2013-03-13 2015-10-08 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
WO2015038958A1 (en) 2013-09-13 2015-03-19 California Institute Of Technology Selective recovery
PT3459965T (pt) 2013-10-11 2021-02-25 Massachusetts Eye & Ear Infirmary Métodos de previsão de sequências de vírus ancestrais e suas utilizações
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
JP6768686B2 (ja) 2014-11-28 2020-10-14 ヴィジョニスティ オイ 眼科治療用器具
USD878575S1 (en) 2015-11-24 2020-03-17 Visionisti Oy Hand operated medical instrument
MA44873A (fr) 2016-04-15 2019-03-13 Univ Pennsylvania Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
CA3019665A1 (en) 2016-04-15 2017-10-19 Curran Matthew Simpson Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
WO2019067540A1 (en) 2017-09-27 2019-04-04 Regenxbio Inc. TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB
CA3079565A1 (en) * 2017-10-18 2019-04-25 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
US11071824B2 (en) 2017-11-04 2021-07-27 Altaviz, Llc Injection devices and methods for making and using them
US10912883B2 (en) 2017-11-04 2021-02-09 Altaviz, Llc Gas-powered fluid injection system

Also Published As

Publication number Publication date
EP4021936A1 (en) 2022-07-06
TW202122419A (zh) 2021-06-16
US20220280608A1 (en) 2022-09-08
BR112022003811A2 (pt) 2022-11-16
AU2020336314A1 (en) 2022-04-07
JP2022545967A (ja) 2022-11-01
WO2021041373A1 (en) 2021-03-04
CN114502197A (zh) 2022-05-13
WO2021041373A8 (en) 2023-01-05
KR20220051246A (ko) 2022-04-26
CA3149401A1 (en) 2021-03-04
IL290863A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
Rahimy et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema
MX2022002366A (es) Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
Vajaranant et al. Visual acuity and intraocular pressure after Descemet's stripping endothelial keratoplasty in eyes with and without preexisting glaucoma
Chang et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration
Spitzer et al. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema
Nguyen et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
Rehak et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study)
Freund et al. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab
Berger et al. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME
Hassanaly et al. Outcomes following Boston type 1 keratoprosthesis implantation in aniridia patients at the University of Montreal
Patil et al. Corneal changes in childhood glaucoma
Cagatay et al. Long–Term Comparison of Fibrin Tissue Glue and Vicryl Suture in Conjunctival Autografting for Pterygium Surgery
Ozturk et al. Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema
Dolezal et al. Glaucoma and cornea surgery outcomes in Peters anomaly
Ogawa et al. Aetiology-specific comparison of long-term outcome of deep anterior lamellar keratoplasty for corneal diseases
Guzel et al. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema
Al Arfaj Boston keratoprosthesis–clinical outcomes with wider geographic use and expanding indications–a systematic review
Hatz et al. Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study
Lipp et al. Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis
Ganekal et al. Early outcomes of primary pediatric keratoplasty in patients with acquired, atraumatic corneal pathology
Nguyen et al. Descemet stripping with automated endothelial keratoplasty: a comparative study of outcome in patients with preexisting glaucoma
Eibenberger et al. Effects of intravitreal dexamethasone implants on retinal oxygen saturation, vessel diameter, and retrobulbar blood flow velocity in ME secondary to RVO
Vasudev et al. Intravitreal bevacizumab for neovascular glaucoma
AR119834A1 (es) TRATAMIENTO DE RETINOPATÍA DIABÉTICA CON Fab ANTI-VEGF COMPLETAMENTE HUMANO MODIFICADO DESPUÉS DE LA TRADUCCIÓN
A Das et al. Combined treatment modalities for age related macular degeneration